Active Filter(s):
Details:
This agreement provides an opportunity for Vectura to realise value from its historical research and investment in VR588, whilst expanding its CDMO development services portfolio by supporting the product's further development with Kinaset.
Lead Product(s): VR588
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: VR588
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Vectura Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 30, 2020